Enliven Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants | Enliven Therapeutics

Funding Rounds

▤ Summary

Enliven Therapeutics priced an underwritten public offering of common stock and pre-funded warrants. The company expects to raise about $200 million before fees and expenses. The offering includes an option for underwriters to buy additional shares within 30 days. Enliven will use the capital as a clinical-stage biopharmaceutical company focused on precision oncology and small molecule therapeutics.

$ Funding

$
Amount $200.0M Total raised
□
Date June 16, 2025 Announcement date
◎
Investors Leucadia National Corp, Goldman Sachs Asset Management, TD Securities, Mizuho Financial Group Lead investors
▥
Company - Funded company

▥ Classifications

industries
No industries detected
applications
Web and Content Management

◇ AskAI Classifications

Labels
No AI classifications detected

▦ Linked Companies